Affiliations: [a] UK Dementia Research Institute, Cardiff University, Cardiff, UK
| [b] Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
Correspondence:
[*]
Correspondence to: Valentina Escott-Price, UK Dementia Research Institute, Cardiff University, 1.03 - Office D, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK. E-mail: escottpricev@cardiff.ac.uk. and Peter Holmans, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, 2.09, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK. E-mail: holmanspa@cardiff.ac.uk.
Note: [1] Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at http://adni.loni.ucla.edu/wpcontent/uploads/how_to_apply/ADNI_Authorship_List.pdf).
Abstract: Background:The rate of cognitive decline in Alzheimer’s disease (AD) has been found to vary widely between individuals, with numerous factors driving this heterogeneity. Objective:This study aimed to compute a measure of cognitive decline in patients with AD based on clinical information and to utilize this measure to explore the genetic architecture of cognitive decline in AD. Methods:An in-house cohort of 616 individuals, hereby termed the Cardiff Genetic Resource for AD, as well as a subset of 577 individuals from the publicly available ADNI dataset, that have been assessed at multiple timepoints, were used in this study. Measures of cognitive decline were computed using various mixed effect linear models of Mini-Mental State Examination (MMSE). After an optimal model was selected, a metric of cognitive decline for each individual was estimated as the random slope derived from this model. This metric was subsequently used for testing the association of cognitive decline with apolipoprotein E (APOE) genotype. Results:No association was found between the number of APOE ɛ2 or ɛ4 alleles and the rate of cognitive decline in either of the datasets examined. Conclusion:Further exploration is required to uncover possible genetic variants that affect the rate of decline in patients with AD.
